MorphoSys AG (WBO:MOR) EV-to-Revenue

: 10.48 (As of Today)

View and export this data going back to 2017. Start your Free Trial

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, MorphoSys AG's enterprise value is €2,498.8 Mil. MorphoSys AG's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was €238.4 Mil. Therefore, MorphoSys AG's EV-to-Revenue for today is 10.48.

The historical rank and industry rank for MorphoSys AG's EV-to-Revenue or its related term are showing as below:

WBO:MOR' s EV-to-Revenue Range Over the Past 10 Years
Min: -0.03 Med: 14.94 Max: 62.31
Current: 10.48

During the past 13 years, the highest EV-to-Revenue of MorphoSys AG was 62.31. The lowest was -0.03. And the median was 14.94.

WBO:MOR's EV-to-Revenue is ranked worse than
57.36% of 1032 companies
in the Biotechnology industry
Industry Median: 7.615 vs WBO:MOR: 10.48

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-18), MorphoSys AG's stock price is €67.70. MorphoSys AG's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was €6.94. Therefore, MorphoSys AG's PS Ratio for today is 9.75.

MorphoSys AG EV-to-Revenue Historical Data

The historical data trend for MorphoSys AG's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MorphoSys AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

52.87

7.02

2.62

0.87

5.17

MorphoSys AG Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-Revenue																0.87	-0.03	1.84	3.38	5.17

Competitive Comparison

For the Biotechnology subindustry, MorphoSys AG's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MorphoSys AG EV-to-Revenue Distribution

For the Biotechnology industry and Healthcare sector, MorphoSys AG's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where MorphoSys AG's EV-to-Revenue falls into.

MorphoSys AG EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

MorphoSys AG's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	2498.795	/	238.361
	=	10.48

MorphoSys AG's current Enterprise Value is €2,498.8 Mil.
MorphoSys AG's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €238.4 Mil.

MorphoSys AG (WBO:MOR) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

MorphoSys AG's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	67.70	/	6.944
	=	9.75

MorphoSys AG's share price for today is €67.70.
MorphoSys AG's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €6.94.

MorphoSys AG EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of MorphoSys AG's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

MorphoSys AG (WBO:MOR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MorphoSys AG (WBO:MOR) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

MPSYF:USA MOR:USA 1MOR:Italy MORd:UK 0NDV:UK MOR:Germany

Address

Semmelweisstrasse 7, Planegg, BY, DEU, 82152

Website

https://www.morphosys.com

MorphoSys AG is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapies for people living with cancer and autoimmune diseases. MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. Tremfya (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys antibody technology to receive regulatory approval. The U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma.